|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Table 8. Hazard Quotient (HQ) and Excess Cancer Risk (ECR) values calculated using the Reference Dose (RfD) for HQ calculation (HQ = ADD/RfD) (Table 8A) and Slope Factor (SF) for ECR calculation (ECR = LADD x SF) (Table 8B). The values of the RfD and SF are included in the ISS/ISPESL 2009 database (ISS/ISPESL, 2009). HQs for all PAHs are summed to provide an overall Hazard Index (HI). When HI ≤ 1 there are no concern for potential adverse systemic health effects in the exposed individuals. Summing the individual ECR for all PAHs, it provides the Cumulative Excess Cancer Risk (ΣECR), that is acceptable if < 10-6 (USEPA, 2009) [39]. |